Clinical features of patients with carbapenem nonsusceptible Klebsiella pneumoniae and Escherichia coli in intensive care units: A nationwide multicenter study in Taiwan

Journal of Microbiology, Immunology and Infection

Volumn 48, Issue 2, 2015, Pages 219-225

  Chang, Yea Yuan ^a,b   Chuang, Yin Ching ^c   Siu, L Kristopher ^d   Wu, Tsu Lan ^e   Lin, Jung Chung ^f   Lu, Po Liang ^g,h   Wang, Jann Tay ⁱ   Wang, Lih Shinn ^j   Lin, Yi Tsung ^a,b   Huang, Ling Ju ^a,b   Fung, Chang Phone ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^f TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

ⁱ NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^j BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

more..

Author keywords

Carbapenem; Escherichia coli; Intensive care unit; Klebsiella pneumoniae

Indexed keywords

AMIKACIN; BACTERIAL ENZYME; BETA LACTAMASE AMPC; CARBAPENEM; CARBAPENEMASE; CIPROFLOXACIN; COLISTIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; IMIPENEMASE 8; KLEBSIELLA PNEUMONIAE CARBAPENEMASE 2; LEVOFLOXACIN; MEROPENEM; NEW DELHI METALLO BETA LACTAMASE 1; OUTER MEMBRANE PROTEIN; TIGECYCLINE; UNCLASSIFIED DRUG; VERONA INTEGRON ENCODED METALLO BETA LACTAMASE; ANTIINFECTIVE AGENT; BETA LACTAMASE; CARBAPENEM DERIVATIVE;

AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CARBAPENEM NONSUSCEPTIBLE KLEBSIELLA PNEUMONIAE INFECTION; CARBAPENEM NONSUSCEPTIBLE ESCHERICHIA COLI INFECTION; CLINICAL FEATURE; ESCHERICHIA COLI INFECTION; FEMALE; HOSPITAL; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTICENTER STUDY; RISK FACTOR; SEPTIC SHOCK; TAIWAN; ADULT; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; DRUG EFFECTS; ENTEROBACTERIACEAE; ESCHERICHIA COLI INFECTIONS; GENETICS; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; ENTEROBACTERIACEAE; ESCHERICHIA COLI INFECTIONS; FEMALE; HOSPITALS; HUMANS; INTENSIVE CARE UNITS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RISK FACTORS; SURVIVAL ANALYSIS; TAIWAN;

EID: 84924529509     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2014.05.010     Document Type: Article

References (25)

1. Tzouvelekis L.S., Markogiannakis A., Psichogiou M., Tassios P.T., Daikos G.L. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012, 25:682-707.
2. Carvalhaes C.G., Cayo R., Gales A.C. Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in the intensive care unit: a real challenge to physicians, scientific community, and society. Shock 2013, 39:32-37.
3. van Duin D., Kaye K.S., Neuner E.A., Bonomo R.A. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis 2013, 75:115-120.
4. Orsi G.B., Falcone M., Venditti M. Surveillance and management of multidrug-resistant microorganisms. Expert Rev Anti Infect Ther 2011, 9:653-679.
5. Swaminathan M., Sharma S., Poliansky Blash S., Patel G., Banach D.B., et al. Prevalence and risk factors for acquisition of carbapenem-resistant Enterobacteriaceae in the setting of endemicity. Infect Control Hosp Epidemiol 2013, 34:809-817.
6. Centers for Disease Control and Prevention (CDC) Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 2013, 62:165-170.
7. Nordmann P., Dortet L., Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm!. Trends Mol Med 2012, 18:263-272.
8. Gupta N., Limbago B.M., Patel J.B., Kallen A.J. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011, 53:60-67.
9. Wu J.J., Wang L.R., Liu Y.F., Chen H.M., Yan J.J. Prevalence and characteristics of ertapenem-resistant Klebsiella pneumoniae isolates in a Taiwanese university hospital. Microb Drug Resist 2011, 17:259-266.
10. Liu S.W., Chang H.J., Chia J.H., Kuo A.J., Wu T.L., Lee M.H. Outcomes and characteristics of ertapenem-nonsusceptible Klebsiella pneumoniae bacteremia at a university hospital in Northern Taiwan: a matched case-control study. J Microbiol Immunol Infect 2012, 45:113-119.
11. Yan J.J., Wu J.J., Lee C.C., Ko W.C., Yang F.C. Prevalence and characteristics of ertapenem-nonsusceptible Escherichia coli in a Taiwanese university hospital, 1999 to 2007. Eur J Clin Microbiol Infect Dis 2010, 29:1417-1425.
12. Tseng S.H., Lee C.M., Lin T.Y., Chang S.C., Chang F.Y. Emergence and spread of multi-drug resistant organisms: think globally and act locally. J Microbiol Immunol Infect 2011, 44:157-165.
13. Munoz-Price L.S., Quinn J.P. Deconstructing the infection control bundles for the containment of carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis 2013, 26:378-387.
14. Hyle E.P., Ferraro M.J., Silver M., Lee H., Hooper D.C. Ertapenem-resistant Enterobacteriaceae: risk factors for acquisition and outcomes. Infect Control Hosp Epidemiol 2010, 31:1242-1249.
15. Debby B.D., Ganor O., Yasmin M., David L., Nathan K., Ilana T., et al. Epidemiology of carbapenem resistant Klebsiella pneumoniae colonization in an intensive care unit. Eur J Clin Microbiol Infect Dis 2012, 31:1811-1817.
16. Lee C.M., Liao C.H., Lee W.S., Liu Y.C., Mu J.J., Lee M.C., et al. Outbreak of Klebsiella pneumoniae carbapenemase-2-producing K. pneumoniae sequence type 11 in Taiwan in 2011. Antimicrob Agents Chemother 2012, 56:5016-5022.
17. Chiu S.K., Wu T.L., Chuang Y.C., Lin J.C., Fung C.P., Lu P.L., et al. National surveillance study on carbapenem non-susceptible Klebsiella pneumoniae in Taiwan: the emergence and rapid dissemination of KPC-2 carbapenemase. PLoS One 2013, 8:e69428.
18. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing: Twenty-Second Informational Supplement M100-S22 2012, Clinical and Laboratory Standards Institute, Wayne, PA.
19. European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0 ed 2013, Available:, [accessed 06.04.13]. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_Breakpoint_table_v_3.0.pdf.
20. Department of Health and Human Services, Food and Drug Administration Class II special controls guidance document: antimicrobial susceptibility test systems (AST): guidance for industry 2009, Washington, DC. USA. Available:, [accessed 06.04.13]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM169359.pdf.
21. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
22. Jean S.S., Lee W.S., Hsueh P.R. Nationwide spread of Klebsiella pneumoniae carbapenemase-2-producing K. pneumoniae sequence type 11 in Taiwan. J Microbiol Immunol Infect 2013, 46:317-319.
23. Kontopidou F., Giamarellou H., Katerelos P., Maragos A., Kioumis I., Trikka-Graphakos E., et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect 2014, 20:O117-O123.
24. Falagas M.E., Lourida P., Poulikakos P., Rafailidis P.I., Tansarli G.S. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 2014, 58:654-663.
25. Huang S.R., Liu M.F., Lin C.H., Shi Z.Y. Molecular surveillance and clinical outcomes of carbapenem-resistant Escherichia coli and Klebsiella pneumoniae infections. J Microbiol Immunol Infect 2014, 47:187-196.